enGene

Forbion European Acquisition Corp. (Nasdaq: FRBN), sponsored by Forbion, a Netherlands-based life sciences venture capital firm, completed its business combination with enGene, a clinical-stage gene therapy company focused on bladder cancer treatments. The SPAC, which went public in 2022 and targeted the biotech and pharmaceutical sector, announced the merger in May 2023, with the transaction subsequently closing and enGene beginning to trade on Nasdaq under the ticker ENGN. The deal represents one of the few European-sponsored SPACs to successfully close a combination with a North American clinical-stage biotech. Visit SpacDesk and sign up for full data, filings, and analytics on FRBN and hundreds of other SPAC transactions.

SPAC Counterparty (1)